Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
April 09 2018 - 07:30AM
Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage
biopharmaceutical company focused on the development of precision
medicines for oncology, today announced that three abstracts
relating to the company’s lead product candidate, tipifarnib, and
ERK inhibitor, KO-947, will be presented at the upcoming American
Association for Cancer Research (AACR) Annual Meeting 2018, which
will be held from April 14-18, 2018 in Chicago. The following
abstracts are now available on the AACR website at www.aacr.org.
Tipifarnib is Highly Active in HRAS Mutant Lung Squamous
Carcinoma TumorModels (Abstract #
4917)Session Category: Experimental and Molecular
TherapeuticsSession Title: Pharmacokinetics and
PharmacodynamicsSession Date and Time: Tuesday, April 17, 2018,
1:00 p.m. - 5:00 p.m.Location: McCormick Place South, Exhibit Hall
A, Poster Section 41
11q13 Amplification Selects for Sensitivity to the ERK
Inhibitor KO-947 inSquamous Cell Carcinomas
(Abstract # 3885)Session Category: Experimental and
Molecular TherapeuticsSession Title: Pharmacogenetics and
PharmacogenomicsSession Date and Time: Tuesday, April 17, 2018,
8:00 a.m. - 12:00 p.m.Location: McCormick Place South, Exhibit Hall
A, Poster Section 37
Preclinical Activity of Tipifarnib in Cutaneous T-cell
Lymphoma (Abstract # 1873)Session Category: Experimental
and Molecular TherapeuticsSession Title: Experimental Agents and
Combinations for Hematologic Malignancies 2Session Date and Time:
Monday, April 16, 2018, 8:00 a.m. - 12:00 p.m.Location: McCormick
Place South, Exhibit Hall A, Poster Section 38
Following presentation at the meeting, the posters will be
available on Kura's website at www.kuraoncology.com.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company
committed to realizing the promise of precision medicines for the
treatment of cancer. The company’s pipeline consists of small
molecule drug candidates that target cancer signaling pathways
where there is a strong scientific and clinical rationale to
improve outcomes by identifying those patients most likely to
benefit from treatment. Kura Oncology’s lead drug candidate is
tipifarnib, a farnesyl transferase inhibitor, which is currently
being studied in multiple Phase 2 clinical trials in solid tumor
and hematologic indications. The company plans to initiate the
AIM-HN trial, a single-arm, registration-directed trial of
tipifarnib in at least 59 recurrent or metastatic patients with
HRAS mutant squamous cell head and neck cancer (HNSCC) in the
second half of 2018. Kura’s pipeline also includes KO-947, an ERK
inhibitor, currently in a Phase 1 trial, and KO-539, an inhibitor
of the menin-MLL protein-protein interaction, currently in
preclinical development. For additional information about Kura
Oncology, please visit the company’s website at
www.kuraoncology.com.
Forward-Looking Statements
This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual
results to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Such forward-looking statements include statements
regarding, among other things, the efficacy, safety and therapeutic
potential of the company’s product candidates, progress and
expected timing of Kura Oncology’s drug development programs and
clinical trials and plans regarding future clinical trials and
development activities. Factors that may cause actual results to
differ materially include the risk that compounds that appeared
promising in early research or clinical trials do not demonstrate
safety and/or efficacy in later preclinical studies or clinical
trials, the risk that Kura Oncology may not obtain approval to
market its product candidates, uncertainties associated with
performing clinical trials, regulatory filings and applications,
risks associated with reliance on third parties to successfully
conduct clinical trials, the risks associated with reliance on
outside financing to meet capital requirements, and other risks
associated with the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. You are urged to consider statements that include the
words "may," "will," "would," "could," "should," "believes,"
"estimates," "projects," "promise, " "potential," "expects,"
"plans," "anticipated," "intends," "continues," "designed," "goal,"
or the negative of those words or other comparable words to be
uncertain and forward-looking. For a further list and description
of the risks and uncertainties the company faces, please refer to
the company's periodic and other filings with the Securities and
Exchange Commission, which are available at www.sec.gov. Such
forward-looking statements are current only as of the date they are
made, and Kura Oncology assumes no obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts
Company:Pete De SpainVice President, Investor Relations
&Corporate Communications(858)
500-8803pete@kuraoncology.com
Investors:Robert H. UhlManaging DirectorWestwicke Partners,
LLC(858) 356-5932robert.uhl@westwicke.com
Media:Jason SparkManaging DirectorCanale Communications(619)
849-6005jason@canalecomm.com
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kura Oncology (NASDAQ:KURA)
Historical Stock Chart
From Mar 2023 to Mar 2024